Examining the Impact of Age on Chemotherapy Effectiveness among Lung Cancer Patients

Introduction: Lung cancer remains a prevalent type of cancer that affects many people and causes their death. Variations in chemotherapy effectiveness among different age groups of lung cancer patients can influence treatment outcomes, necessitating an investigation into age-specific responses to chemotherapy. The research aims to examine the impact of age on chemotherapy effectiveness among lung cancer (LC) patients, focusing on overall survival time, response rate, and comorbidity scores across different age categories. Methods: A total of 300 lung cancer patients undergoing chemotherapy were surveyed. Patients were divided into three age groups: ≤ 50 years, 50–69 years, and ≥ 70 years. Data analysis was performed using SPSS 25, employing descriptive statistics, regression analysis, correlation analysis, and ANOVA to evaluate factors affecting chemotherapy outcomes. Result: Descriptive statistics revealed the highest average survival time of 36 months with a response rate of 90%. Regression analysis identified an intercept of 62.00, with negative coefficients associated with increasing age and advanced disease stage. Correlation analysis showed a positive correlation of 0.45 between response rate and survival time. ANOVA indicated an average response rate of 67.8% among patients aged below 50, suggesting a potential benefit in tailored treatment strategies for younger patients. Conclusion: These results support the treatment of patients with lung cancer, according to their age in an attempt to improve the outcomes of chemotherapy sessions. The research highlights a need for further research into age-related factors that influence treatment outcomes, emphasizing personalized approaches for improved patient care.